October 19th 2020
By Skylar Jeremias
Reviewers found that costs of reference infliximab and its biosimilars make it the most cost-effective therapy for ulcerative colitis (UC) among targeted immune modulators.
October 15th 2020
By Tony Hagen
DaxibotulinumtoxinA met all end points in a study demonstrating longer duration of action, safety, and tolerability.
October 14th 2020
Alexion and Celltrion separately announce advances in their drug development and marketing efforts.
October 13th 2020
Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.
The US Public Interest Research Group (PIRG) contends AbbVie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers.
October 9th 2020
The product would target the lucrative, billion-dollar worldwide market for Xolair.
October 6th 2020
A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.
The agreement enables Reliance Life Sciences to springboard into the US market using Medicure's commercial reach.
September 30th 2020
The Federal Trade Commission's powers to bring antitrust actions are circumscribed by public versus private and what is vs isn't "reasonable," Markus H. Meier explained.
September 29th 2020
California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.
